Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference.

Published on Jan 1, 2021in JAMA Oncology24.799
· DOI :10.1001/JAMAONCOL.2020.5161
Kendal Jensen1
Estimated H-index: 1
(UW: University of Washington),
Eric Q. Konnick15
Estimated H-index: 15
(UW: University of Washington)
+ 9 AuthorsColin C. Pritchard51
Estimated H-index: 51
(UW: University of Washington)
Importance Cell-free DNA (cfDNA) testing is increasingly used in the treatment of patients with advanced prostate cancer. Clonal hematopoiesis of indeterminate potential (CHIP) can interfere with cfDNA testing and cause incorrect interpretation of results. There is an urgent need to better understand this problem following recent US Food and Drug Administration approval of poly(ADP) ribose polymerase inhibitors (PARPi) for metastatic prostate cancer based on variants in DNA repair genes that can be affected by CHIP. Objective To determine the prevalence of clinically relevant CHIP interference in prostate cancer cfDNA testing. Design, setting, and participants We report a case series of 69 patients with advanced prostate cancer (metastatic disease or with rising PSA following localized therapy) who had cfDNA variant testing with a large panel cancer next generation sequencing assay (UW-OncoPlexCT). To determine the source of variants in plasma, we tested paired cfDNA and whole blood control samples. The study was carried out in an academic medical center system reference laboratory. Main outcomes and measures Prevalence and gene spectrum of CHIP interference in patients with prostate cancer undergoing cfDNA testing. Results We detected CHIP variants at 2% or more variant fraction in cfDNA from 13 of 69 men with prostate cancer (19%; 95% CI, 10%-30%). Seven men (10%; 95% CI, 4%-20%) had CHIP variants in DNA repair genes used to determine PARPi candidacy, including ATM (n = 5), BRCA2 (n = 1), and CHEK2 (n = 1). Overall, CHIP variants accounted for almost half of the somatic DNA repair gene variants detected. Participant CHIP variants were exponentially correlated with older age (R2 = 0.82). CHIP interference variants could be distinguished from prostate cancer variants using a paired whole-blood control. Conclusions and relevance In this case series, approximately 10% of men with advanced prostate cancer had CHIP interference in plasma cfDNA in DNA repair genes that are used for eligibility of PARPi therapy, most frequently in ATM. Clinical cfDNA testing should include a paired whole-blood control to exclude CHIP variants and avoid misdiagnosis.
📖 Papers frequently viewed together
9 Citations
19 Citations
#1Wassim Abida (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 24
#2David Alan Campbell (Barwon Health)H-Index: 6
Last. Simon Chowdhury (Sarah Cannon Research Institute)H-Index: 11
view all 27 authors...
Purpose: Genomic alterations in DNA damage repair (DDR) genes other than BRCA may confer synthetic lethality with PARP inhibition in metastatic castration-resistant prostate cancer (mCRPC). To test this hypothesis, the phase 2 TRITON2 study of rucaparib included patients with mCRPC and deleterious non-BRCA DDR gene alterations. Patients and Methods:TRITON2 enrolled patients who had progressed on 1 to 2 lines of next-generation androgen receptor (AR)-directed therapy and 1 taxane-based chemothera...
90 CitationsSource
#1Johann S. de BonoH-Index: 124
#2Joaquin MateoH-Index: 37
Last. Maha Hussain (NU: Northwestern University)H-Index: 13
view all 20 authors...
BACKGROUND: Multiple loss-of-function alterations in genes that are involved in DNA repair, including homologous recombination repair, are associated with response to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition in patients with prostate and other cancers. METHODS: We conducted a randomized, open-label, phase 3 trial evaluating the PARP inhibitor olaparib in men with metastatic castration-resistant prostate cancer who had disease progression while receiving a new hormonal agen...
324 CitationsSource
#1Ayako J. Kuo (University of Washington Medical Center)H-Index: 1
#2Vera A. Paulson (University of Washington Medical Center)H-Index: 4
Last. Christina M. Lockwood (University of Washington Medical Center)H-Index: 1
view all 10 authors...
Abstract Objectives The rapid discovery of clinically significant genetic variants has translated to next-generation sequencing assays becoming out-of-date by the time they are designed, validated, and implemented. UW-OncoPlex addresses this through the adoption of a modular panel capable of redesign as significant alterations are identified. We describe the validation of OncoPlex version 6 (OPXv6) for the detection of single nucleotide variants (SNVs), insertions and deletions (indels), copy nu...
8 CitationsSource
#1Jack V. W. Bacon (UBC: University of British Columbia)H-Index: 5
#2Matti Annala (UTA: University of Tampere)H-Index: 25
Last. Lucia Nappi (UBC: University of British Columbia)H-Index: 13
view all 12 authors...
Abstract Purpose There is a lack of molecularly-informed biomarkers for patients with metastatic renal cell carcinoma (RCC). Plasma cell-free DNA (cfDNA) sequencing is a minimally-invasive alternative to tissue for profiling the genome in other cancers but relevance in metastatic RCC remains unclear. Materials and Methods Whole blood was collected from 55 metastatic RCC patients. Plasma cfDNA and leukocyte DNA were subjected to targeted sequencing across 981 cancer genes. Matched tumour tissue f...
8 CitationsSource
#1Pedram Razavi (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 28
#2Bob T. Li (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 33
Last. Jorge S. Reis-Filho (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 133
view all 43 authors...
Accurate identification of tumor-derived somatic variants in plasma circulating cell-free DNA (cfDNA) requires understanding of the various biological compartments contributing to the cfDNA pool. We sought to define the technical feasibility of a high-intensity sequencing assay of cfDNA and matched white blood cell DNA covering a large genomic region (508 genes; 2 megabases; >60,000× raw depth) in a prospective study of 124 patients with metastatic cancer, with contemporaneous matched tumor tiss...
189 CitationsSource
#1Thomas P. Slavin (City of Hope National Medical Center)H-Index: 18
#2Bradford CoffeeH-Index: 4
Last. Debora Mancini-DiNardoH-Index: 5
view all 9 authors...
Abstract Next-generation sequencing (NGS) hereditary pan-cancer panel testing can identify somatic variants, which exhibit lower allele frequencies than do germline variants and may confound hereditary cancer predisposition testing. This analysis examined the prevalence and characteristics of likely-somatic variants among 348,543 individuals tested using a clinical NGS hereditary pan-cancer panel. Variants showing allele frequencies between 10% and 30% were interpreted as likely somatic and iden...
11 CitationsSource
#2Roman GulatiH-Index: 34
Last. Colin C. PritchardH-Index: 51
view all 11 authors...
BACKGROUND: Plasma-based cell-free DNA is an attractive biospecimen for assessing somatic mutations due to minimally-invasive real-time sampling. However, next generation sequencing (NGS) of cell-free DNA (cfDNA) may not be appropriate for all patients with advanced prostate cancer (PC). METHODS: Blood was obtained from advanced PC patients for plasma-based sequencing. UW-OncoPlex, a ∼2 Mb multi-gene NGS panel performed in the CLIA/CAP environment, was optimized for detecting cfDNA mutations. Tu...
9 CitationsSource
#1Jeffrey N. Weitzel (City of Hope National Medical Center)H-Index: 70
#2Elizabeth C. Chao (UCI: University of California, Irvine)H-Index: 26
Last. Kory JaspersonH-Index: 13
view all 18 authors...
Blood/saliva DNA is thought to represent the germ line in genetic cancer-risk assessment. Cases with pathogenic TP53 variants detected by multigene panel testing are often discordant with Li-Fraumeni syndrome, raising concern about misinterpretation of acquired aberrant clonal expansions (ACEs) with TP53 variants as germ-line results. Pathogenic TP53 variants with abnormal next-generation sequencing metrics (e.g., decreased ratio (<25%) of mutant to wild-type allele, more than two detected allel...
62 CitationsSource
#1Matti Annala (UBC: University of British Columbia)H-Index: 19
#1Matti Annala (UBC: University of British Columbia)H-Index: 25
Last. Kim N. Chi (UBC: University of British Columbia)H-Index: 77
view all 18 authors...
Primary resistance to androgen receptor (AR) directed therapies in metastatic castration-resistant prostate cancer (mCRPC) is poorly understood. We randomized 202 treatment-naive mCRPC patients to abiraterone or enzalutamide, and performed whole exome and deep targeted 72-gene sequencing of plasma cell-free DNA prior to therapy. For these agents, which have never been directly compared, time to progression was similar. Defects in BRCA2 and ATM were strongly associated with poor clinical outcomes...
202 CitationsSource
#1Gonzalo Torga (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 9
#2Kenneth J. Pienta (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 138
This cohort study examines the reliability and potential utility of 2 commercially available liquid biopsy assays for reported mutations in cell-free DNA.
116 CitationsSource
Cited By12
#1Krupal B. Patel (UWO: University of Western Ontario)H-Index: 5
#2Nicholas Cormier (UWO: University of Western Ontario)
Last. Danielle MacNeil (UWO: University of Western Ontario)H-Index: 9
view all 0 authors...
Objective. Detection of circulating tumor DNA (ctDNA) in cancer patients can potentially serve as a noninvasive, sensitive test of disease status. The purpose of this study was to determine the ability to detect BRAF (V600E) mutations in the plasma of patients with thyroid nodules, with the goal of distinguishing between benign and malignant nodules. Methods. Consecutive patients with thyroid nodules who consented for surgery were recruited. Plasma samples were obtained preoperatively and one mo...
#1Scott A. TomlinsH-Index: 85
#2Daniel H. HovelsonH-Index: 22
Last. Jamil KhatriH-Index: 3
view all 0 authors...
PURPOSETissue-based comprehensive genomic profiling (CGP) is increasingly used for treatment selection in patients with advanced cancer; however, tissue availability may limit widespread implementa...
#1Andrea Necchi (UniSR: Vita-Salute San Raffaele University)H-Index: 13
#2Vito Cucchiara (UniSR: Vita-Salute San Raffaele University)H-Index: 14
Last. Shakti H. Ramkissoon (Foundation Medicine)H-Index: 17
view all 21 authors...
Background null This study assessed the contrasting genomic profiles from the primary tumors (PTs), metastatic (MET) sites, and circulating tumor DNA (ctDNA) of patients with prostate cancer (PC). null Methods null A total of 1294 PC tissue specimens and 2462 ctDNA specimens underwent hybrid capture-based comprehensive genomic profiling (CGP). Specimens included tissue from PTs; MET biopsies from bone, liver (LIV), lung (LU), brain (BN), lymph node, and soft tissue sites; and ctDNA. null Results...
#1Cameron Herberts (UBC: University of British Columbia)H-Index: 5
#2Alexander W. Wyatt (UBC: University of British Columbia)H-Index: 35
Circulating tumor DNA (ctDNA) enables real-time genomic profiling of cancer without the need for tissue biopsy. ctDNA-based technology is seeing rapid uptake in clinical practice due to the potential to inform patient management from diagnosis to advanced disease. In metastatic disease, ctDNA can identify somatic mutations, copy-number variants (CNVs), and structural rearrangements that are predictive of therapy response. However, the ctDNA fraction (ctDNA%) is unpredictable and confounds varian...
#1Michael T. Schweizer (UW: University of Washington)H-Index: 25
#2Smruthy Sivakumar (Foundation Medicine)
Last. Bruce Montgomery (Prostate Cancer Foundation)H-Index: 34
view all 10 authors...
Importance DNA damage repair (DDR) gene mutations represent actionable alterations that can guide precision medicine strategies for advanced prostate cancer. However, acquisition of contemporary tissue samples for molecular testing can be a barrier to deploying precision medicine approaches. We hypothesized that most DDR alterations represent truncal events in prostate cancer and that primary tissue would faithfully reflect mutations found in cell-free circulating tumor DNA (ctDNA) and/or metast...
#1Hanna Tukachinsky (Foundation Medicine)H-Index: 1
#2Russell Madison (Foundation Medicine)H-Index: 12
Last. Geoffrey R. Oxnard (Foundation Medicine)H-Index: 1
view all 22 authors...
Purpose: Comprehensive genomic profiling (CGP) is of increasing value for patients with metastatic castration-resistant prostate cancer (mCRPC). mCRPC tends to metastasize to bone, making tissue biopsies challenging to obtain. We hypothesized CGP of cell-free circulating tumor DNA (ctDNA) could offer a minimally invasive alternative to detect targetable genomic alterations that inform clinical care. Experimental Design: Using plasma from 3,334 patients with mCRPC (including 1,674 screening sampl...
9 CitationsSource
#1Elizabeth GreenH-Index: 3
Last. Ashish M. Kamat (University of Texas MD Anderson Cancer Center)H-Index: 76
view all 8 authors...
Abstract Context Bladder and kidney cancers require invasive procedures for definitive diagnosis, and bladder cancer requires repeated procedures to monitor for disease recurrence. Given the recent work to identify molecular alterations in liquid biopsies to diagnose and monitor these diseases, a synthesis of the growing body of evidence is merited. Objective To review current data on cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) and to synthesize their roles in the diagnosis, monitori...
1 CitationsSource
#1Nathan M Hawkey (Duke University)H-Index: 1
#2Andrew J. Armstrong (Duke University)H-Index: 63
Liquid biopsy is a promising clinical tool that can provide critical information for prognostication and which may inform treatment decisions in men with metastatic castration resistant prostate cancer (mCRPC). Here we discuss the Foundation Medicine plasma cell free tumor DNA (ctDNA) assay, its pros and cons, and potential clinical utility.
1 CitationsSource
#1Julie EarlH-Index: 14
#2Emma BarretoH-Index: 1
Last. Alfredo CarratoH-Index: 67
view all 13 authors...
Pancreatic ductal adenocarcinoma (PDAC) presents many challenges in the clinic and there are many areas for improvement in diagnostics and patient management. The five-year survival rate is around 7.2% as the majority of patients present with advanced disease at diagnosis that is treatment resistant. Approximately 10-15% of PDAC cases have a hereditary basis or Familial Pancreatic Cancer (FPC). Here we demonstrate the use of circulating free DNA (cfDNA) in plasma as a prognostic biomarker in PDA...
1 CitationsSource
#1Sarah W S Ng (UBC: University of British Columbia)
#2Alexander W. Wyatt (UBC: University of British Columbia)H-Index: 35
Genomic alterations in metastatic castration-resistant prostate cancer can be identified in plasma circulating tumour DNA. A large cohort analysis shows reliable detection of clinically relevant alterations through targeted cell-free DNA sequencing with a commercial platform, paving the way for liquid biopsy technology to be integrated into routine clinical practice.